Associations between lifetime classic psychedelic use and cardiometabolic diseases
Otto Simonsson, Walter Osika, Robin Carhart-Harris, Peter S. Hendricks
Scientific Reports July 13, 2021 DOI: 10.1038/s41598-021-93787-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cross-sectional survey Peer reviewed |
|---|---|
| Population | Respondents from the National Survey on Drug Use and Health (2005–2014) |
| Keywords | Odds ratio Disease Diabetes mellitus Cardiovascular health Demography Gerontology |
| Citations | 54 |
| Key findings | Lifetime classic psychedelic use was associated with lower odds of past-year heart disease (aOR = 0.77) and lower odds of past-year diabetes (aOR = 0.88). |
Abstract
Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65–0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78–0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.
Citations in the library
Cited by 49
- Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment Neuropharmacology January 13, 2023
- Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study Scientific Reports February 16, 2022
- Psychedelics in the treatment of unipolar and bipolar depression International Journal of Bipolar Disorders July 5, 2022
- Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling Neuropharmacology August 17, 2022
- Classic psychedelics, health behavior, and physical health. Therapeutic Advances in Psychopharmacology 2022
and 44 more in the library
Cites 15
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psychedelics as anti-inflammatory agents International Review of Psychiatry July 4, 2018
- The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization. Frontiers in Pharmacology March 2, 2016
- The Current Status of Psychedelics in Psychiatry. JAMA Psychiatry February 1, 2021
and 10 more in the library